Payment overview · 2025
General Payments
$999.16
61 reported records · 15 companies
Healthcare provider profile · identity verified
Matthew John Windrow, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HONDO, TX · NPI 1487673935
Verified facts
What the public records show
CMS Open Payments records show Matthew John Windrow, M.D. received $999.16 in general payments during 2025 across 61 reported records.
ABBVIE INC. accounted for 27.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 225 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $272.76 | 27.3% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $252.24 | 25.2% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $171.11 | 17.1% | 11 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $51.39 | 5.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.94 | 4.8% | 3 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $32.61 | 3.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.04 | 2.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.56 | 2.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $21.22 | 2.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.22 | 1.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.16 | 1.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.07 | 1.7% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.51 | 1.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.86 | 1.4% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $13.47 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $999.16 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $235.54 | 16 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $131.82 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $102.56 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $53.02 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $51.39 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $47.94 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $37.22 | 4 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $32.61 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.55 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.55 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $28.04 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.56 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $9.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 135 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 171 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
135 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
171 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
225 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Meloxicam | Meloxicam | 721 | 196 |
| Atorvastatin Calcium | Atorvastatin Calcium | 708 | 189 |
| Lisinopril | Lisinopril | 662 | 174 |
| Methylprednisolone | Methylprednisolone | 587 | 432 |
| Amlodipine Besylate | Amlodipine Besylate | 580 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 552 | 131 |
| Gabapentin | Gabapentin | 549 | 131 |
| Metoprolol Succinate | Metoprolol Succinate | 539 | 131 |
| Metformin Hcl | Metformin Hcl | 513 | 127 |
| Losartan Potassium | Losartan Potassium | 481 | 116 |
| Tamsulosin Hcl | Tamsulosin Hcl | 456 | 111 |
| Escitalopram Oxalate | Escitalopram Oxalate | 407 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 381 | 91 |
| Furosemide | Furosemide | 380 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 371 | 105 |
| Azithromycin | Azithromycin | 329 | 255 |
| Potassium Chloride | Potassium Chloride | 319 | 73 |
| Alprazolam | Alprazolam | 317 | 64 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 288 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 280 | 81 |
| Zolpidem Tartrate | Zolpidem Tartrate | 280 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 278 | 98 |
| Omeprazole | Omeprazole | 260 | 72 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 258 | 66 |
| Trazodone Hcl | Trazodone Hcl | 253 | 58 |
| Donepezil Hcl | Donepezil Hcl | 246 | 55 |
| Montelukast Sodium | Montelukast Sodium | 230 | 59 |
| Eliquis | Apixaban | 225 | 35 |
| Simvastatin | Simvastatin | 221 | 56 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 216 | 99 |
| Tramadol Hcl | Tramadol Hcl | 208 | 60 |
| Carvedilol | Carvedilol | 195 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 191 | 47 |
| Celecoxib | Celecoxib | 184 | 37 |
| Ozempic | Semaglutide | 171 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 169 | 50 |
| Prednisone | Prednisone | 168 | 118 |
| Ezetimibe | Ezetimibe | 164 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 138 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 137 | 28 |
| Mounjaro | Tirzepatide | 135 | 19 |
| Amoxicillin | Amoxicillin | 129 | 110 |
| Glipizide | Glipizide | 129 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 128 | 38 |
| Alendronate Sodium | Alendronate Sodium | 127 | 34 |
| Metformin Hcl Er | Metformin Hcl | 127 | 36 |
| Allopurinol | Allopurinol | 126 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 121 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 120 | 85 |
| Fluoxetine Hcl | Fluoxetine Hcl | 119 | 21 |
| Januvia | Sitagliptin Phosphate | 116 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 52 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 114 | 28 |
| Sertraline Hcl | Sertraline Hcl | 114 | 30 |
| Ibuprofen | Ibuprofen | 108 | 49 |
| Ropinirole Hcl | Ropinirole Hcl | 106 | 23 |
| Buspirone Hcl | Buspirone Hcl | 104 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 33 |
| Sucralfate | Sucralfate | 100 | 25 |
| Levetiracetam | Levetiracetam | 97 | 16 |
| Pregabalin | Pregabalin | 97 | 22 |
| Lorazepam | Lorazepam | 94 | 23 |
| Aripiprazole | Aripiprazole | 92 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 24 |
| Glyburide | Glyburide | 89 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 89 | 37 |
| Glimepiride | Glimepiride | 87 | 25 |
| Finasteride | Finasteride | 85 | 19 |
| Cefdinir | Cefdinir | 84 | 66 |
| Cephalexin | Cephalexin | 84 | 57 |
| Atenolol | Atenolol | 81 | 20 |
| Primidone | Primidone | 81 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 17 |
| Baclofen | Baclofen | 77 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 76 | 56 |
| Famotidine | Famotidine | 75 | 22 |
| Clonidine Hcl | Clonidine Hcl | 71 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 68 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 16 |
| Memantine Hcl | Memantine Hcl | 64 | 15 |
| Meclizine Hcl | Meclizine Hcl | 63 | 19 |
| Glipizide Er | Glipizide | 62 | 14 |
| Ondansetron Odt | Ondansetron | 62 | 30 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 60 | 36 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 59 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 22 |
| Mirtazapine | Mirtazapine | 58 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 58 | 11 |
| Jardiance | Empagliflozin | 57 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 27 |
| Metoclopramide Hcl | Metoclopramide Hcl | 55 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 53 | 13 |
| Enalapril Maleate | Enalapril Maleate | 50 | 13 |
| Levofloxacin | Levofloxacin | 49 | 39 |
| Propranolol Hcl | Propranolol Hcl | 49 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 46 | suppressed |
| Spironolactone | Spironolactone | 46 | 20 |
| Divalproex Sodium | Divalproex Sodium | 44 | 12 |
| Jantoven | Warfarin Sodium | 44 | suppressed |
| Temazepam | Temazepam | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 11 |
| Mupirocin | Mupirocin | 42 | 21 |
| Acyclovir | Acyclovir | 41 | 24 |
| Bupropion Xl | Bupropion Hcl | 41 | 11 |
| Lovastatin | Lovastatin | 41 | 12 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 26 |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Risperidone | Risperidone | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 34 | 24 |
| Fluconazole | Fluconazole | 34 | 25 |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | 13 |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 33 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 33 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | 12 |
| Latanoprost | Latanoprost | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 17 |
| Irbesartan | Irbesartan | 29 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 29 | 11 |
| Bumetanide | Bumetanide | 27 | suppressed |
| Carbamazepine | Carbamazepine | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Dutasteride | Dutasteride | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 19 |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Carisoprodol | Carisoprodol | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 25 | 25 |
| Rybelsus | Semaglutide | 25 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 24 | 12 |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Constulose | Lactulose | 20 | suppressed |
| Enulose | Lactulose | 20 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 19 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 19 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | 11 |
| Metolazone | Metolazone | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Travoprost | Travoprost | 17 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 14 | 12 |
| Ssd | Silver Sulfadiazine | 14 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 13 |
| Nystatin | Nystatin | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $999.16 · 61 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CONTRAVE, Dexcom G6 Transmitter, FARXIGA, INGREZZA, INSPIRE, MOUNJARO, NEXLETOL, Ozempic, QULIPTA, QUTENZA, REXULTI, Rybelsus, Senza, The Cologuard Plus Collection Kit, UBRELVY, UZEDY, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error